KIDNEY CANCER DRUGS MARKET ANALYSIS
The kidney cancer drugs market is estimated to be valued at USD 6.89 billion in 2024 and is expected to reach USD 10.31 billion by 2031, exhibiting a compound annual growth rate (CAGR) of 5.9% from 2024 to 2031. Rising prevalence of kidney cancer worldwide owing to changing lifestyles and growing geriatric population are the major factors driving the demand for effective treatment drugs.
To learn more about this report, request a free sample copy
The market is witnessing positive growth owing to increasing demand for targeted drugs for kidney cancer treatment. Many pipeline drugs are under development which would provide better efficacy and reduced side effects. As these drugs receive regulatory approvals, they would capture significant market share and substitute existing approved drugs. Moreover, rising awareness about early diagnosis and treatment availability is further projected to aid market growth during the forecast period.
Rising Prevalence of Risk Factors
The increasing prevalence of risk factors for kidney cancer such as obesity, hypertension, and smoking is expected to significantly drive the market growth. Kidney cancer risk is strongly associated with obesity, with overweight and obese individuals having up to twice the risk of developing the disease compared to those with a healthy weight. With obesity rates rising sharply all over the world, more people are becoming vulnerable to kidney cancer. For instance, over 70% of American adults are either overweight or obese currently according to government data. This translates to a huge population at high risk. For example, according to the American Society of Clinical Oncology (ASCO), in February 2022, kidney cancer was diagnosed in 79,000 persons in the U.S. in 2022 (50,290 males and 28,710 women). 2020 saw an estimated 431,288 cases of kidney cancer diagnosed globally. Kidney cancer is sixth among cancers that affect men in the U.S. For women, it ranks as the seventh most prevalent cancer. Kidney cancer patients are often diagnosed between the ages of 65 and 74, with an average diagnostic age of 64. According to the National Center for Biotechnology Information, almost 270,000 new instances of renal cell carcinoma (RCC) were diagnosed globally in 2018. RCC makes up around 4% of all adult malignancies.
To learn more about this report, request a free sample copy
Targeted Therapy - A Revolution in Treatment
The development of targeted drug therapies in recent years has revolutionized the treatment of kidney cancer. These targeted drugs inhibit specific molecules involved in cancer cell growth and survival, proving much more effective than traditional chemotherapy drugs. A major breakthrough was the advent of tyrosine kinase inhibitors that block the vascular endothelial growth factor receptor pathway critical for tumor angiogenesis. Drugs like Sutent, Inlyta, and Cabometyx gained quick approvals and popularity due to their superior efficacy over chemotherapy. Immunotherapy is another breakthrough approach gaining widespread usage. Checkpoint inhibitors that help activate the immune system against cancer cells have significantly improved treatment outcomes for many types of advanced kidney cancer. Blockbuster drugs such as Opdivo and Keytruda are at the forefront of the immunotherapy revolution for kidney cancer treatment. Their ability to induce long lasting remissions even in late-stage patients is truly remarkable. With continuous advances being made in targeted therapies and newer immunotherapies in the pipeline, personalized medicine seems poised to take over as the dominant treatment paradigm. This fundamental shift to more effective drugs and longer durations of therapy will fuel significant growth in spending on kidney cancer medications.
Key Takeaways of Analyst:
The kidney cancer drugs market is expected to grow steadily driven by the rising prevalence of renal cell carcinoma globally. North America and Europe currently dominate the market due to high awareness and developed healthcare infrastructure. However, Asia Pacific is likely to witness the fastest growth owing to growing healthcare expenditure and increasing penetration of healthcare insurance.
The market has a positive outlook based on strong product pipeline and growing research into combination therapy regimens. Existing drugs will continue to witness rising demand along with the launch of newer targeted therapies for advanced kidney cancer indications. Affordability may remain a concern for certain types of costly drugs in developing regions.
Biosimilars are expected to have a restraining impact on the market once patents expire for some blockbuster drugs. However, their limited initial uptake is expected to prevent a major revenue dip for incumbent vendors. Data exclusivity and tough regulatory norms in some regions pose challenges for biosimilar approval and commercialization.
Market Challenges: Lack of effective treatment options
One of the major challenges this market faces is the lack of effective treatment options for late-stage kidney cancer. While some drugs have increased survival rates for early-stage patients, relapse and drug resistance continues to be a problem. The overall approvals of new drugs are also low due to high failure rates in clinical trials. Another challenge is the presence of various sub-types of kidney cancer, each with its own genetic patterns and response to treatment. Developing drugs that can target multiple sub-types effectively is difficult. Further, the costs of R&D for precision medicines and immunotherapies are very high, acting as a deterrent for smaller companies.
Market Opportunities: Increasing funding for kidney cancer
Government initiatives and increasing funding for kidney cancer research presents a major opportunity for growth in the kidney cancer drugs market. Kidney cancer is a serious health issue affecting many lives every year. However, with more support and resources dedicated to advancing treatment methods, there is hope that outcomes can improve significantly over the coming years. For instance, in September 2022, Weill Cornell Medicine secured a three-year grant worth USD 1 million from the Department of Defense's Kidney Cancer Research Program. The funding aims to support investigations into the function of the protein ATF4 in clear cell renal cell carcinoma (ccRCC), a type of kidney cancer.
To learn more about this report, request a free sample copy
Insights, By Therapy: The proliferation of targeted cancer therapies drives the dominance of targeted therapy segment
In terms of therapy, targeted therapy is expected to contribute the highest share of the market, accounting for 49.50% in 2024 owing to advancements in precision medicines and molecular targeted drugs designed to specifically attack cancer cells. Revolutionary targeted agents such as tyrosine kinase inhibitors, mTOR inhibitors, and angiogenesis inhibitors have transformed the treatment landscape by offering higher response rates, improved quality of life, and better overall survival compared to conventional chemotherapies. Key targeted drugs approved for kidney cancer include sunitinib, pazopanib, axitinib, and everolimus which received wider adoption as first-line and sequential options. Continuous research exploring the genetic mutations and pathways underlying clear cell renal carcinoma also led to a stream of novel targeted therapies entering the pipeline and market. With their higher specificity and improved tolerability profile, targeted therapies have become the standard of care for frontline and relapsed metastatic kidney cancer, driving the leadership of this segment.
Insights, By Pharmacological Class: Rise of combination immunotherapy elevates Angiogenesis Inhibitors segment
In terms of pharmacological class, angiogenesis inhibitors is expected to contribute the highest share of the market, accounting for 40.12% in 2024 owing to paradigm-shifting results from immunotherapy combinations. Angiogenesis inhibitors were a pioneering targeted class and include bevacizumab and sorafenib. While monotherapy efficacy was modest, recent studies revealed significantly improved outcomes when angiogenesis inhibitors are given with immunotherapy drugs such as nivolumab. The CheckMate -214 trial showed the axitinib-nivolumab combination doubling progression-free survival versus sunitinib alone, setting a new treatment standard. Based on such transformational data, guidelines now recommend angiogenesis inhibitor-based combinations as preferred first-line regimens. The unprecedented success of these regimens have made angiogenesis inhibitors the mainstay targeted agents in modern kidney cancer care, driving the large market share of this segment.
Insights, By Distribution Channel: Hospital pharmacies lead due to the management of complex regimens
In terms of distribution channel, hospital pharmacies is expected to contribute the highest share of the market, accounting for 59.12 % in 2024 owing to the complex nature of various kidney cancer treatments requiring active pharmacy involvement. Targeted therapies and immunotherapy regimens often involve delicate schedules, strict storage guidelines, and intensive adverse event monitoring which hospitals are better equipped to optimize. Nurses in hospital settings can closely check drug administration, infusion times, and manage any side effects under expert medical supervision. Additionally, the high costs of many novel kidney cancer drugs lead to much of their dispensing being controlled by hospitals. Retail pharmacies and growing online channels complement access but advanced therapies continue to consolidate around specialty hospitals where multidisciplinary teams can deliver stringent protocol-based care. This specialized management competency of hospital pharmacies has helped strengthen their foothold as the foremost distribution segment for kidney cancer medicines.
To learn more about this report, request a free sample copy
North America has established itself as the dominant region in the global kidney cancer drugs market.with share of 40.2 % in 2024. The presence of leading pharmaceutical companies and existence of advanced healthcare infrastructure has enabled extensive R&D activities and clinical trials in the region. Most of the major kidney cancer drugs were initially approved by FDA for sale in the U.S.. Being an early adopter of new treatment options, oncologists in the region frequently prescribe the latest kidney cancer drugs compared to other regions. This has resulted in North America accounting for the largest share of global sales. Several pharmaceutical companies have their global headquarters located in the U.S., which invests heavily in developing novel treatment options for the effective management of kidney cancer.
Asia Pacific is emerging as the fastest growing market for kidney cancer drugs. Rising healthcare expenditure, growing focus on cancer treatment, and increasing patient population base are some of the key factors fuelling the market growth. The high cost of kidney cancer treatment remains a challenge for development of the market. However, the growing medical tourism industry coupled with the availability of more affordable generic drugs is slowly overcoming this barrier. Countries like China and India offer cost effective kidney cancer treatment options compared to developed markets, attracting patients from other Asian and African nations. This is positively impacting the kidney cancer drug imports and sales in the Asia Pacific region. With improving standards of living and rising disposable income, Asian patients are increasingly opting for advanced treatment methods and innovative drugs. This changing healthcare landscape is anticipated to drive the kidney cancer drugs market during the forecast period.
Kidney Cancer Drugs Market Report Coverage
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 6.89 Bn |
| Historical Data for: | 2019 To 2023 | Forecast Period: | 2024 To 2031 |
| Forecast Period 2024 to 2031 CAGR: | 5.9% | 2031 Value Projection: | US$ 10.31 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, Roche Holding AG (Genentech, Inc.), Bayer AG, Exelixis, Inc., Merck & Co., Inc., Eisai Co., Ltd., Aveo Pharmaceuticals, AstraZeneca PLC, Ipsen Biopharmaceuticals, Inc., GlaxoSmithKline plc, Abbott Laboratories Source, Amgen Inc. , Calithera Biosciences, Inc., Active Biotech, Immatics Biotechnologies GmbH, Karyopharm Therapeutics |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
*Definition: The kidney cancer drugs market consists of pharmaceutical drugs that are used to treat kidney cancer. The market includes drugs from different drug classes that are used to target different molecular pathways involved in the development and progression of kidney cancers. Some of the major drug classes included in this market are targeted therapies such as tyrosine kinase inhibitors, mTOR inhibitors, angiogenesis inhibitors; immunotherapies such as checkpoint inhibitors; and chemotherapies.
Kidney Cancer Drugs Market Report Snapshots
Frequently Asked Questions
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowWant to Buy a Report but have a Limited Budget?
We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request Discount
Reliability and Reputation
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India :